EFA Technologies develops RevDx, a portable diagnostic blood lab that uses microscopy and AI to identify pathogens, analyze biomarkers and deliver rapid, accurate results including a full CBC from a single drop of blood. RevDx is designed to be portable, affordable and user-friendly, aiming to reduce costs and time while improving the doctor–patient relationship. The company packages multi-channel capabilities—automatic microscopy and bio-sensing readers—into a platform intended to support additional diagnostic applications and an ecosystem of image-processed algorithms. EFA holds CE certification and secured ANVISA approval for RevDx, enabling its market entry into Brazil and prompting exploration of other international markets. Financially, EFA announced it secured US$6.5 million in growth capital to accelerate product development, expand market reach and foster further innovation. The company is backed by a medical board including Nobel Laureate Prof. Aaron Ciechanover. Engineering for All is developing RevDx©, a digital diagnostic programmable lab-on-hand system that the article says can enable fully automated microscopy diagnostics and real-time disease mapping through a handheld, real-time multichannel solution. The device is described as portable and self-powered, with full CBC and parasitology capabilities, infectious-disease diagnosis, and features intended to enable precise and affordable test-treat-track treatment. The company is working on a functional prototype and has won several awards in Israel; it has also presented with delegations in India and Taiwan. Financially, the company raised $900k in seed funding. The investment came from eHealth Ventures, an Israeli digital-health technological incubator led by CEO Yoel Ezra. Engineering for All is based in Tel Aviv, Israel.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2024